NLS drug-2

Ultimovacs has adjusted guidance from the first half of 2023 to the second half of 2023 for communication of topline progression free survival (PFS) data from the INITIUM Phase II trial in malignant melanoma patients. “We are encouraged that disease progression in the INITIUM trial is slower than anticipated when compared with historical data. This […]

SynAct Pharma has completed patient recruitment to the company’s clinical trial EXPAND which is evaluating its lead candidate compound AP1189 in early Rheumatoid Arthritis (RA) patients with severe disease activity. With all patients included into the study, dosing will be concluded in July and the last patient’s safety follow-up visit to be conducted in August. […]

Herantis Pharma has announced the dosing of the first healthy volunteer in the Phase 1a clinical study for HER-096. The Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. “We are excited to start the Phase 1a clinical study with HER-096. This is an important milestone on our […]

Nykode Therapeutics has announced results from the VB-C-02 trial, investigating the use of Nykode’s therapeutic cancer vaccine candidate VB10.16 in combination with Roche’s cancer immunotherapy Tecentriq in patients with advanced or recurrent, non-resectable HPV16-positive cervical cancer. “We are extremely encouraged by the unprecedented data that indicates a doubling of the survival of PD-L1+ patients with […]

Evaxion Biotech has announced preclinical data demonstrating the effectiveness of its AI-driven viral vaccine discovery platform. The presented preclinical study was conducted in collaboration with associate professor Girish Kirimanjeswara, Pennsylvania State University, US. Our RAVEN platform represents a paradigm shift in vaccine development, identifying vaccine candidates against any existing, newly emerging, and mutating viral diseases […]

Affibody have shared long-term 46-week data from a global Phase 2 trial of izokibep in psoriatic arthritis (PsA). The randomized double-blind, placebo-controlled, Phase 2 clinical trial evaluated the safety and efficacy of izokibep dosed 80 mg every two weeks (Q2W) or 40 mg Q2W, versus placebo Q2W, in adult patients with active PsA. The global […]